Skip to main content
Contact Us
Subscribe
E-Edition
62°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunovant, Inc. - Common Stock
(NQ:
IMVT
)
18.79
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Immunovant, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
10 Health Care Stocks Whale Activity In Today's Session
September 18, 2023
Via
Benzinga
Where Immunovant Stands With Analysts
September 18, 2023
Via
Benzinga
If You Invested $1000 In Vivek Ramaswamy-Founded Roivant When He Declared Presidential Bid, Here's How Much You'd Have Now
August 25, 2023
Roivant stock has outperformed the broader market and the biotech sector this year, mirroring the rise in the fortunes of its founder Vivek Ramaswamy.
Via
Benzinga
What 11 Analyst Ratings Have To Say About Immunovant
August 16, 2023
Via
Benzinga
Immunovant's FcRn Strategy Gains Momentum: Analysts View ADHERE Study as De-Risking Factor for CIDP Clinical Development
July 18, 2023
Monday, Argenx SE (NASDAQ: ARGX) reported topline results from the ADHERE study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with chronic inflammatory demyelinating...
Via
Benzinga
9 Analysts Have This to Say About Immunovant
July 18, 2023
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Immunovant: Here's What You Need To Know
May 23, 2023
Via
Benzinga
Immunovant Inc. (NASDAQ: IMVT) is a Stock Spotlight on 5/23
May 23, 2023
Via
Investor Brand Network
Analyst Expectations for Immunovant's Future
May 23, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
July 17, 2023
It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday!
Via
InvestorPlace
Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session
July 17, 2023
U.S. stock futures traded mixed this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Recap: Immunovant Q4 Earnings
May 22, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
May 01, 2023
Via
Benzinga
Analyst Expectations for Immunovant's Future
April 25, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023
April 25, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023
March 31, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
March 30, 2023
Via
Benzinga
7 Analysts Have This to Say About Immunovant
March 30, 2023
Via
Benzinga
Immunovant Inc. (NASDAQ: IMVT) is a Stock Spotlight on 3/24
March 24, 2023
Via
Investor Brand Network
Analyst Boosts Immunovant Price Target After Updated Pipeline Realignment
March 20, 2023
Via
Benzinga
Immunovant Could Potentially Be An M&A Target, Writes Analyst
February 15, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 13, 2023
February 13, 2023
Via
Benzinga
Analyst Expectations for Immunovant's Future
February 07, 2023
Via
Benzinga
What 6 Analyst Ratings Have To Say About Immunovant
November 08, 2022
Within the last quarter, Immunovant (NASDAQ:IMVT) has observed the following analyst ratings:
Via
Benzinga
Where Immunovant Stands With Analysts
November 07, 2022
Immunovant (NASDAQ:IMVT) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2023
February 15, 2023
Via
Benzinga
Universal Health Services, Madrigal Pharmaceuticals And These Overbought Majors In The Healthcare Sector
December 23, 2022
The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Immunovant: Q2 Earnings Insights
November 04, 2022
Immunovant (NASDAQ:IMVT) reported its Q2 earnings results on Friday, November 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
6 Analysts Have This to Say About Immunovant
November 08, 2022
Over the past 3 months, 6 analysts have published their opinion on Immunovant (NASDAQ:IMVT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th
November 07, 2022
From
Immunovant Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.